Once Daily Immunosuppression Regimen
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/4/2018 |
| Start Date: | June 4, 2018 |
| End Date: | June 2021 |
| Contact: | Rowena Delos Santos, MD |
| Email: | delossantos@wustl.edu |
| Phone: | 314-362-8351 |
Once a Day Immunosuppression Regimen: Outcomes and Compliance
The purpose of this research study is to determine whether an immunosuppressive maintenance
regimen of Envarsus/azathioprine compared to a tacrolimus/ mycophenolic acid regimen is
associated with better compliance, tolerability, and lower biopsy proven rejection.
regimen of Envarsus/azathioprine compared to a tacrolimus/ mycophenolic acid regimen is
associated with better compliance, tolerability, and lower biopsy proven rejection.
Inclusion Criteria:
- Age >/= 18 years old
- Kidney transplant recipient
- Thymoglobulin induction
Exclusion Criteria:
- Non-renal organ transplant
- Combined organ transplant
- Inability to receive Envarsus after transplant
- Discharged to acute care facility after transplant
We found this trial at
1
site
Click here to add this to my saved trials
